期刊文献+

卵巢肿瘤患者血浆溶血磷脂酸测定及临床意义 被引量:3

Detection and clinical significance of serum level of lysophosphatidic acid in patients with ovarian tumor
下载PDF
导出
摘要 目的探讨卵巢肿瘤患者血浆溶血磷脂酸(LPA)表达水平及其临床意义。方法观察LPA对卵巢癌细胞增殖力的影响;测定卵巢癌患者48例、卵巢良性肿瘤患者20例及14例健康妇女的血浆LPA水平,并作对比分析。结果 LPA可增加细胞的增殖能力,且存在剂量依赖性。正常妇女和卵巢良性肿瘤患者血浆LPA水平无统计学意义;卵巢上皮性癌患者血浆LPA水平显著高于正常妇女和良性卵巢上皮性肿瘤患者(P<0.01)。结论 LPA与卵巢癌的发生发展相关,对卵巢上皮性癌的诊断和病情监测具有潜在的临床应用价值。 Objective To study the serum levels of lysophosphatidie acid (LPA) in patients with ovarian tumor and its clinical significance. Methods Observe the proliferation ability of the ovarian cancer cell by LPA deal with;48 patients with ovarian tumor,20 patients with benign ovarian tumors and 14 normal women were subjected to detect the serum levels of LPA and for comparative analysis. Results LPA promotes cell proliferation showing a dose-dependency. Levels of serum LPA in patients with epithelial ovarian cancer were higher significantly than those of normal women and benign cases( P 〈0. 01 ). Conclusion LPA is related to the development of ovarian cancer. LPA may have a potential value for diagnosis of epithelial ovarian cancer.
出处 《延安大学学报(医学科学版)》 2012年第2期4-6,共3页 Journal of Yan'an University:Medical Science Edition
基金 延安市科技计划项目 2011ks-33
关键词 溶血磷脂酸 卵巢肿瘤 Lysophosphatidic acid Ovarian tumor
  • 相关文献

参考文献8

  • 1Sakamoto S, Yokoyama M, Zhang X, et al. Increased expres- sion of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by ly- sophosphatidic acid [ J ]. Endocrinology, 2004, 145 ( 6 ) : 2929-2940.
  • 2Mills GB, May C, McGill M, et al. A putative new growth factor inascitic fluid from ovanrian cancer patients:identifi- cation, charaterization, andmechanism of action [ J ]. Can- cerRes, 1988,48 : 1066-1071.
  • 3Shen Z, Wu M, Elson P, et al. Fatty acid composition of lyso- phosphatidic acid and lysophosphatidylinosital in plasma from patients with ovarian cancer and other gynecological diseases[ J]. Gynecol, Oncol 2001,83 ( 1 ) :25-30.
  • 4Ren J, Xiao Y J, Singh L S, et al. Lysophosphatidic acid is constitutively producedby human peritoneal mesothelial ceils and enhances adhesion, migration, and invasion of ovar- ian cancer cells[J]. Cancer Res,2006,66 (6) :3006-3014.
  • 5Base T, Batbaros M, Baykara E, et al. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow up of patients with epithe- lial ovarian cancer [ J ]. Gynecol Oncol, 2010,21 ( 4 ) : 248- 254.
  • 6Hu YL, Albanese C, PestellRG, et al. Dualmechanisms for lysophosphatidic acid stimulation oihuman ovarian carcinoma cells[ J ]. Natl Cancer Inst,2003,95 (10) :733-740.
  • 7丁萍萍,李强.溶血磷脂酸促卵巢癌细胞增殖机制的研究[J].山东大学学报(医学版),2011,49(7):35-38. 被引量:4
  • 8Sutphen R, Yan Xu, Wilbanks D, et al. Lysophospholipids are potential biomarkers of ovarian cancer [ J ]. Cancer Epi- demiology Biomarkers Prevention,2004,13 (7) : 1185-1191.

二级参考文献12

  • 1李宗斌,陈玉霞,赵洁莹,卢建.药物治疗浓度的雌激素对卵巢癌3AO细胞生长的影响(英文)[J].Acta Genetica Sinica,2006,33(9):782-792. 被引量:3
  • 2Zeng P, Wagoner H A, Pescovitz O H, et al. RNA inter- ference (RNAi) for extracellular signal-regulated kinase I (ERK1) alone is sufficient to suppress cell viability in o- varian cancer cells[J].Cancer Biol Ther, 2005, 4 ( 9 ) : 961-967.
  • 3Ren J, Xiao Y J, Singh L S, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells[J].Cancer Res, 2006, 66 ( 6 ) : 3006-3014.
  • 4Base T, Batbaros M, Baykara E, et al. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow up of patients with epithelial ovarian cancer [ J]. Gynecol Oncol, 2010, 21 (4) :248-254.
  • 5Lee C W, Kim N H, Choi H K, et al. Lysophosphatidic acid-induced c-fos up-regulation involves cyclic AMP re- sponse element-binding protein activated by mitogen- and stress-activated protein kinase-1 [ J ]. Cell Biochem, 2008, 104:785-794.
  • 6Hu Y L, Albanese C, Pestell R G, et al. Dual mecha- nisms for lysophosphatidic acid stimulation of human o-varian carcinoma cells [ J ]. Natl Cancer Inst, 2003, 95 (10) :733-740.
  • 7Symowicz J, Adley B P, Woo M M, et al. Cyclooxyge- nase-2 functions as a downstream mediator of lysophos- phatidic acid to promote aggressive behavior in carcino- ma cells[J].Cancer Res, 2005, 65(6) :2234-2242.
  • 8Kang S, Luo R, Smicun Y, et al. Selective induction of cyclooxygenase-2 plays a role in lysophosphaticlic acid regulated Fas ligand cell surface presentation[J].FEBS Lett, 2006, 580(2) :443-449.
  • 9Lin C I, Chen C N, Huang M T, et al. Lysophosphatid- ic acid up-regulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA( 1/3 ), COX-2, and NF-kappa B activation and EGFR transactivation-dependent mechanisms[J].Cell Signal, 2008, 20(10):1804-1814.
  • 10孙红,朱青,任娟,吴磊,孔繁忠,李光,胡海峰.溶血磷脂酸对宫颈癌细胞增殖、黏附、迁移和凋亡的影响[J].细胞与分子免疫学杂志,2009,25(8):702-705. 被引量:13

共引文献3

同被引文献61

  • 1王敏,郭丽.卵巢癌患者体内可溶型Fas水平测定及其免疫诊断学意义[J].中华医学研究与实践,2004,2(5):4-5. 被引量:1
  • 2于占彩,李振光,伍期专.溶血磷脂类分子与卵巢癌[J].中国实用医刊,2010,37(21):60-62. 被引量:1
  • 3Chun, J. , et al. , International Union of Basic and Clinical Pharmacolo- gy. LXXV Ⅲ. Lysophospholipid receptor nomenclature [ J]. Pharmacol Rev,2010. 62(4) :579-587.
  • 4Smyth, S. S. , et al. Roles of lysophosphatidic acid in cardiovascular physiology and disease [ J ]. Biochim Biophys Acta, 2008,1781 ( 9 ) : 563 -570.
  • 5Rancoule,C. ,et al. Lysophosphatidic acid-l-receptor targeting agents for fibrosis[J]. Expert Opin lnvestig Drugs ,2011,20 (5) :657-667.
  • 6Noguchi, K. , et al. Lysophosphatidic acid ( LPA ) and its receptors [ J]. Curr Opin Pharmacol,2009,9( 1 ) : 15-23.
  • 7Kurth, T. , H. Chabriat and M. G. Bousser, Migraine and stroke: a complex association with clinical implications [ J ]. Lancet Neurol, 2012,11 ( 1 ) :92-100.
  • 8Schurks, M. , et al. Migraine and mortality: a systematic review and meta-analysis[ J]. Cephalalgia,2011,31 (12) :1301-1314.
  • 9Li, Z. G. , et al. , Influence of acetylsalicylate on plasma lysophospha- tidic acid level in patients with ischemic cerebral vascular diseases [J]. Neurol Res,2008,30(4) :366-369.
  • 10Kopp, U, C. ,M. Z. Cicha and S. Y. Jones, Activation of endothelin A receptm,'s contributes to impaired responsiveness of renal mechanosen- sory nerves in congestive heart failure[ Jl. Can J Physiol Pharmacol, 2010,88(6) :622-629.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部